Skip to main content

Table 3 Clinical and pathomorphological IgAN progression risk factors in studied patients at the time of kidney biopsy and at the end of follow-up in the drug-treated patient’ group

From: Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection

 

MAP (mmHg)

eGFR (ml/min)

U-Prot (g/day)

BMI (kg/m2)

S1/T1 %

At the time of kidney biopsy

 All drug-treated (N = 39)

100.8 ± 13.9

85.7 ± 32.8

1.3 (0–10.2)

27.6 ± 5.4

63.2

 RASb (N = 31)

102.8 ± 14.2*

82.1 ± 32.2*

1.2 (0–10.2)*

28.4 ± 5.4

61.3

 CCB (N = 8)

110.5 ± 16.4

49.5 ± 20.4

3.4 (0.1–10.2)

31.0 ± 6.2

87.5

At the end of follow-up.

 All drug-treated (N = 38)

96.2 ± 9.9

76.5 ± 28.7

1.0 (0–8.5)

27.9 ± 4.9

 

 RASb (N = 30)

95.8 ± 9.6*

73.6 ± 7.4*

1.1 (0–8.5)*

28.4 ± 4.9

 

 CCB (N = 8)

102.7 ± 15.9

44.2 ± 20.9

2.5 (0–8.5)

30.0 ± 3.3

 
  1. RASb renin-angiotensin system blockers, CCB calcium channel blockers, MAP mean arterial pressure, eGFR estimated Glomerular Filtration Rate, M/F male/female, S1 segmental sclerosis/adhesion, T1 tubular atrophy/interstitial fibrosis > 25%
  2. Values are expressed as mean ± standard deviation or percent or range
  3. * p-value < 0.05. The p value compares the RASb subgroups to the groups CCB at the time of kidney biopsy or at the end of follow-up, respectively
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us